Mechanism of EGR2 in Allergic Rhinitis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE1

Total Enrollment

3 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-01-30

Study Completion Date

2023-05-05

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

EGR2 may be a target for the treatment of nasal polyps.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Treatment of Allergic Rhinitis and Chronic Polypous Rhinosinusitis With Olfactory Mucosa-derived Mesenchymal Stem Cells

NCT05167552

Allergic Rhinitis Rhinosinusitis Chronic

UNKNOWN PHASE1/PHASE2

Study of Chronic Rhinosinusitis Symptoms in Asthma Patients Undergoing Treatment With Reslizumab

NCT03369574

Chronic Rhinosinusitis (Diagnosis) Asthma Nasal Polyps

WITHDRAWN

The Effect of Early Radiofrequency Turbinate Reduction on Persistent Allergic Rhinitis

NCT05276336

Allergic Rhinitis

COMPLETED PHASE3

Characteristic Transcriptomic, Proteomic and Metabolomic Molecular Studies of Nasal Secretions From Chronic Rhinitis

NCT06678334

Chronic Rhinitis

NOT_YET_RECRUITING

Effects of Radiofrequency Ablation of Posterior Nasal Nerves on Inflammatory Cytokines, Peak Nasal Inspiratory Flow, and Nasal Blood Flow in Patients With Chronic Rhinitis

NCT05648565

Chronic Rhinitis

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

There is much debate about the etiology of nasal polyps, so the pathogenesis of nasal polyps still needs to be clarified. Surgery for noninflammatory nasal polyps may be better control, but surgery is not effective for recurrent sinusitis and nasal polyps. Therefore, more research is needed to determine the best targeted therapy for nasal polyps. We found that EGR2 expression was upregulated in CRSwNP patients with allergic rhinitis.In addition, the expression of EGR2 in CRSwNP mucosa was significantly higher than that in the control group, and the expression of EGR2 in CRSwNP with allergic rhinitis was higher than that in CRSwNP without allergic rhinitis. EGR2 may be involved in the pathogenesis of nasal polyps, and may also be related to the severity and recurrence of nasal polyps. EGR2 may be a target for the treatment of nasal polyps.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Rhinitis, Allergic

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

TRIPLE

Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

immunohistochemistry

Thirty-eight patients with confirmed nasal polyps (20 with primary CRSwNP and allergic rhinitis (AR) and 18 with CRSWNP) and 20 patients with chronic hypertrophic rhinitis were included. The nasal polyps and mucosal specimens of all patients were collected and analyzed by immunohistochemistry

Group Type EXPERIMENTAL

EGR2

Intervention Type GENETIC

We investigated the expression of EGR2 in patients with nasal polyps through immunohistochemistry.

WestBlot

Thirty-eight patients with confirmed nasal polyps (20 with primary CRSwNP and allergic rhinitis (AR) and 18 with CRSWNP) and 20 patients with chronic hypertrophic rhinitis were included. The nasal polyps and mucosal specimens of all patients were collected and analyzed by Western Blot.

Group Type EXPERIMENTAL

EGR2

Intervention Type GENETIC

We investigated the expression of EGR2 in patients with nasal polyps through immunohistochemistry.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

EGR2

We investigated the expression of EGR2 in patients with nasal polyps through immunohistochemistry.

Intervention Type GENETIC

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

All patients were stopped by systemic or topical corticosteroid treatment at least one month before the study.

Exclusion Criteria

Patients had NPs accompanied by choanal polyps, fungal nasal sinusitis, cystic fibrosis, acute upper airway upper infection or other systemic diseases.

Minimum Eligible Age

16 Years

Maximum Eligible Age

76 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No